Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2029-05-14
Target enrollment:
Participant gender:
Summary
The primary study objective is to assess progression-free survival in patients with ovarian cancer receiving telmisartan plus selected standard of care chemotherapy regimens versus historical controls.